Combination Therapy for Tumors Co-Expressing EGFR and NeuGcGM3
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies targeting EGFR and N-glycolyl gangliosides (NeuGcGM3) in tumors often fail to demonstrate synergistic antitumor activity, and their practical application in clinical or preclinical studies has not been effectively addressed, leading to inconsistent treatment outcomes in patients with tumors co-expressing these targets.
Innovation Solution
Development of pharmaceutical cancer compositions combining vaccines targeting GM3 N-glycolyl gangliosides and antibodies against EGFR, which can be administered separately or in combination with conventional chemotherapy and radiation, to enhance therapeutic effects in tumors co-expressing both targets, such as lung, breast, and digestive system tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If combination therapy with anti-EGFR antibodies and anti-NeuGcGM3 vaccines is administered, then antitumor activity is enhanced, but treatment complexity increases
Solution Approach 1:
The patent combines two separate therapeutic approaches (anti-EGFR antibody therapy and anti-NeuGcGM3 vaccine therapy) into a unified treatment regimen. This merging of therapies targets two different molecular pathways simultaneously, achieving enhanced antitumor activity through synergistic effects while managing the complexity through coordinated administration protocols
2Reliability
If multiple therapeutic agents are administered simultaneously, then therapeutic effect is enhanced, but ease of operation decreases
Solution Approach 1:
The patent segments the combination therapy into distinct administration components: anti-EGFR antibodies administered via injection and anti-NeuGcGM3 vaccines administered via immunization protocols. This segmentation allows each therapeutic agent to be optimized for its specific delivery method while maintaining overall treatment coordination, thereby preserving ease of operation despite the multifaceted approach
3Reliability
If combination therapy is used to treat tumors co-expressing EGFR and NeuGcGM3, then treatment effectiveness increases, but manufacturing precision requirements increase
Solution Approach 1:
The patent employs parameter changes by adjusting the dosing regimens of anti-EGFR antibodies and anti-NeuGcGM3 vaccines based on tumor characteristics, patient response, and molecular expression levels. This flexible parameter adjustment allows optimization of treatment effectiveness while accommodating variations in manufacturing precision through adaptive dosing protocols
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy shows significant antitumor activity, leading to partial or complete regression of tumors, stabilization of clinical symptoms, and increased survival rates in patients, with improved tolerance and quality of life compared to traditional monotherapies.
Implementation Method 1
Active immunotherapy against NeuGcGM3 in tumors has been published using NeuGcGM3/VSSP molecular vaccine which has demonstrated its immunogenicity and its safety
Implementation Method 2
Treatment with anti-EGFR monoclonal antibodies mediate tumor regression by the interruption of oncogenic signals and the induction of an innate immune response mechanism mediated by the Fc receptor
Data Source
Figure 1A~1F
Figure 2~3B
Figure 4A~4D
AI summary
The present invention relates to pharmaceutical compositions for the treatment of malignant tumors. Particularly those tumors that express EGFR and GM3 N-glycolyl ganglioside targets to enhance the therapeutic effect produced by separated therapies against these targets. The pharmaceutical compositions of the invention include antibodies and/or vaccines against each of the targets. Additionally the present invention relates to methods for applying the compositions of the invention.